TY - JOUR
T1 - A single center retrospective study of daratumumab, pomalidomide, and dexamethasone as 2nd-line therapy in multiple myeloma
AU - Liu, Lawrence
AU - Fiala, Mark
AU - Gao, Feng
AU - King, Justin
AU - Goldsmith, Scott
AU - Wildes, Tanya M.
AU - Stockerl-Goldstein, Keith
AU - Vij, Ravi
AU - Schroeder, Mark A.
N1 - Funding Information:
We thank the Washington University Department of Medicine and Department of Hematology and Oncology at the Siteman Cancer Center for funding support. We thank the patients whose medical information will guide the management of multiple myeloma.
Funding Information:
LWL, FG, MF, JK, and KS: The authors report no conflicts of interest. SG: Consulting: Wugen, Inc. TW: Received research funding from Janssen. Works as a consultant with Carevive Systems and Seattle Genetics. RV: The author received honoraria and travel expenses from Celgene, Onyx, Takeda, Novartis, Merck, Bristol-Myers Squibb, and Janssen, and research funding from Takeda and Onyx. MAS: The author has received research funding and honoraria from Incyte Corporation, Amgen, and Genzyme Sanofi and research funding through his institution from Cellect Inc, Fortis, Genentech, Seattle Genetics, Celgene, PBD Inc, and Janssen. He has served on speaker’s bureau in the past for AbbVie, Merck, and Takeda. He has consulted for and received honoraria from Astellas, Dova Pharmaceuticals, FlatIron Inc, GSK, Gilead Sciences Inc, Novo Nordisk, Partners Therapeutics, and Pfizer.
Publisher Copyright:
© 2021 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2021
Y1 - 2021
N2 - Daratumumab, pomalidomide, and dexamethasone (DPd) is an FDA-approved 3rd or later line of therapy for myeloma. However, as there are limited published data on the efficacy of 2nd-line DPd, we conducted a retrospective analysis (n = 33). Herein, we report our center’s data for 2nd-line DPd. Our patient population had a high amount of high risk cytogenetics (45.5%). The overall response rate (ORR) was 84.9% with a 1-year Progression Free Survival (PFS) of 37.7%. In standard risk myeloma (n = 18), the ORR was 88.9% and 1-year PFS was 61.1% (95% CI 42.3–88.3%). In high risk myeloma (45.5%, n = 15), the ORR was 80% with a 1-year PFS of 7.3% (95% CI 1.1–47.9%). This suggests that the efficacy of 2nd-line DPd in myeloma with high risk cytogenetics should be further investigated.
AB - Daratumumab, pomalidomide, and dexamethasone (DPd) is an FDA-approved 3rd or later line of therapy for myeloma. However, as there are limited published data on the efficacy of 2nd-line DPd, we conducted a retrospective analysis (n = 33). Herein, we report our center’s data for 2nd-line DPd. Our patient population had a high amount of high risk cytogenetics (45.5%). The overall response rate (ORR) was 84.9% with a 1-year Progression Free Survival (PFS) of 37.7%. In standard risk myeloma (n = 18), the ORR was 88.9% and 1-year PFS was 61.1% (95% CI 42.3–88.3%). In high risk myeloma (45.5%, n = 15), the ORR was 80% with a 1-year PFS of 7.3% (95% CI 1.1–47.9%). This suggests that the efficacy of 2nd-line DPd in myeloma with high risk cytogenetics should be further investigated.
KW - Myeloma
KW - antibody-based immunotherapy
KW - chemotherapeutic approaches
KW - cytogenetics
KW - drug resistance
KW - immunotherapy
UR - http://www.scopus.com/inward/record.url?scp=85108183084&partnerID=8YFLogxK
U2 - 10.1080/10428194.2021.1941940
DO - 10.1080/10428194.2021.1941940
M3 - Letter
C2 - 34142630
AN - SCOPUS:85108183084
SN - 1042-8194
VL - 62
SP - 3043
EP - 3046
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 12
ER -